LeonaBio, Inc. (NASDAQ:LONA) — Market Cap & Net Worth
Market Cap & Net Worth: LeonaBio, Inc. (LONA)
LeonaBio, Inc. (NASDAQ:LONA) has a market capitalization of $82.85 Million ($82.85 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19901 globally and #4319 in its home market, demonstrating a 2.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LeonaBio, Inc.'s stock price $8.82 by its total outstanding shares 9393514 (9.39 Million). Analyse LeonaBio, Inc. cash flow conversion to see how efficiently the company converts income to cash.
LeonaBio, Inc. Market Cap History: 2026 to 2026
LeonaBio, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $82.85 Million to $82.85 Million (0.00% CAGR).
LeonaBio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LeonaBio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LONA by Market Capitalization
Companies near LeonaBio, Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to LeonaBio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
LeonaBio, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, LeonaBio, Inc.'s market cap moved from $82.85 Million to $ 82.85 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $82.85 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of LeonaBio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $82.85 Million USD |
| MoneyControl | $82.85 Million USD |
| MarketWatch | $82.85 Million USD |
| marketcap.company | $82.85 Million USD |
| Reuters | $82.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds whic… Read more